Eubiologics Co., Ltd., Eubiologics Co., Ltd., Anyang, Korea.
Toxicol Res. 2012 Dec;28(4):225-33. doi: 10.5487/TR.2012.28.4.225.
The present study was carried out to examine the toxicity and target organs of oral cholera vaccine (OCV) after repeated oral administration in Sprague-Dawley rats for 6 weeks (3 administrations, once every 2 weeks). OCV is an inactivated oral cholera vaccine that contains Vibrio cholerae and confers protection against cholera caused by V. cholera serogroups O1 (Inaba and Ogawa serotypes) and O139 (strain 4260B). The animals were orally administered either OCV placebo (negative control) or OCV at a dose equivalent to 240 times the anticipated human dose. Throughout the administration period, no significant change was detected in clinical signs, body weight, food or water consumption, urinalysis results, hematological and clinical biochemistry test results, organ weights, necropsy, or histopathological examination results. Minor changes were found in hematological and clinical biochemistry tests; however, these changes were within normal ranges. The above results suggest that oral administration of OCV in rats did not induce any toxicologically meaningful changes, and the target organs could not be determined. This study was conducted in accordance with the guidelines established by Good Laboratory Practice (2009-183, KFDA, December 22, 2009) and the OECD Principles of Good Laboratory Practice (1997).
本研究旨在检查经口霍乱疫苗(OCV)在 Sprague-Dawley 大鼠中重复口服给药 6 周(3 次,每 2 周一次)后的毒性和靶器官。OCV 是一种灭活的口服霍乱疫苗,含有霍乱弧菌,可预防由霍乱弧菌血清型 O1(Inaba 和 Ogawa 血清型)和 O139(菌株 4260B)引起的霍乱。动物口服给予 OCV 安慰剂(阴性对照)或相当于 240 倍预期人类剂量的 OCV。在整个给药期间,未检测到临床症状、体重、食物或水的摄入、尿液分析结果、血液学和临床生化学检查结果、器官重量、尸检或组织病理学检查结果的显著变化。血液学和临床生化学检查发现有轻微变化;然而,这些变化仍在正常范围内。上述结果表明,OCV 在大鼠中的口服给药不会引起任何具有毒理学意义的变化,并且无法确定靶器官。本研究是按照良好实验室规范(2009-183,KFDA,2009 年 12 月 22 日)和经合组织良好实验室规范原则(1997 年)进行的。